ライフサイエンスコーパス: malaria vaccine

1 s may aid in the design of a next-generation malaria vaccine.

2 the chances of developing a highly effective malaria vaccine.

3 underway to find an effective and affordable malaria vaccine.

4 complicate efforts to develop a blood stage malaria vaccine.

5 s for the development of a P. falciparum GAP malaria vaccine.

6 y for the development of a live-vector-based malaria vaccine.

7 step in the development of a preerythrocytic malaria vaccine.

8 (42)) is a prime candidate for a blood-stage malaria vaccine.

9 n be used in the development of an effective malaria vaccine.

10 signed candidate sequence for inclusion in a malaria vaccine.

11 the safety and immunogenicity of the AMA1-C1 malaria vaccine.

12 ising new candidate for the development of a malaria vaccine.

13 a leading candidate for inclusion in a human malaria vaccine.

14 ntigen 1 (AMA1) is a leading candidate for a malaria vaccine.

15 a parasites brings us closer to an effective malaria vaccine.

16 d RAP2) are candidate antigens for a subunit malaria vaccine.

17 arly supports its inclusion in a multivalent malaria vaccine.

18 alciparum is a candidate protein for a human malaria vaccine.

19 further increased the need for an effective malaria vaccine.

20 mponent of a multivalent P. falciparum human malaria vaccine.

21 rtant candidate antigen for a multicomponent malaria vaccine.

22 further development of BVp42 as a candidate malaria vaccine.

23 l future development plan for the RTS,S/AS01 malaria vaccine.

24 suitable candidates for the development of a malaria vaccine.

25 EBA-175 as components in a combination of a malaria vaccine.

26 ), will likely be the first publicly adopted malaria vaccine.

27 elop PfRH5 as an urgently needed blood-stage malaria vaccine.

28 del, including the soon-to-be licensed RTS,S malaria vaccine.

29 ly, is the leading candidate for a pregnancy malaria vaccine.

30 , which could contribute to a cost-effective malaria vaccine.

31 ble carrier system(s) for the development of malaria vaccine.

32 proteins as an effective platform to deliver malaria vaccines.

33 otection is unmatched by current recombinant malaria vaccines.

34 ould be important in informing the design of malaria vaccines.

35 shows promise for simple delivery of subunit malaria vaccines.

36 uation would be the development of effective malaria vaccines.

37 l prove critical in the search for effective malaria vaccines.

38 tage protection by candidate preerythrocytic malaria vaccines.

39 nformation may aid in the rational design of malaria vaccines.

40 nt implications for development of effective malaria vaccines.

41 struct genetically modified, live attenuated malaria vaccines.

42 ign of Plasmodium falciparum live attenuated malaria vaccines.

43 most promising candidates for development as malaria vaccines.

44 t for exploiting GPIs for the development of malaria vaccines.

45 e required for the development of successful malaria vaccines.

46 ntifying target antigens for preerythrocytic malaria vaccines.

47 rotective immunity to exo-erythrocytic stage malaria vaccines.

48 parasite, and has been used for making anti-malaria vaccines.

49 tructure-based design of next-generation CSP malaria vaccines.

50 mportant component of pre-erythrocytic human malaria vaccines.

51 egy in the development of highly efficacious malaria vaccines.

52 topes to maximize the response to multistage malaria vaccines.

53 from the first clinical trials of candidate malaria vaccines?

54 hase I dose and route finding study of a new malaria vaccine, a replication-incompetent chimpanzee ad

55 e examined the MBC response to two candidate malaria vaccines administered with or without CpG, a TLR

56 meet this challenge, including an effective malaria vaccine and adequate vector control strategies.

57 between protection induced by a recombinant malaria vaccine and Ag-specific T cell responses.

58 alleles before and after vaccination in the malaria vaccine and control groups and examination of th

59 Large-scale functional genomics studies for malaria vaccine and drug development will depend on the

60 ncing the efficacy of a whole parasite-based malaria vaccine and for designing strategies for the dev

61 ssessed the cross-protective efficacy of the malaria vaccine and inferred which polymorphic amino aci

62 candidate molecule for inclusion in a human malaria vaccine and is strongly conserved in the genus.

63 in the development of an AMA-1 antigen-based malaria vaccine and may also guide testing of AMA-1-base

64 veral candidate vaccines including the RTS,S malaria vaccine and the subunit glycoprotein E varicella

65 order to define the protective efficacy of a malaria vaccine and thus guide programmatic decisions on

66 l in the development of a multispecies human malaria vaccine and vaccines against other infectious di

67 who were receiving RTS,S/AS01 or RTS,S/AS02 malaria vaccine and were undergoing experimental challen

68 Anti-malaria vaccines and drugs could be greatly improved if

69 The development of effective malaria vaccines and immune biomarkers of malaria is a h

70 lly as an adjuvant in cancer, hepatitis, and malaria vaccines and in allergen-specific immunotherapy.

71 iological and immunological requirements for malaria vaccines and the recent history of malaria vacci

72 elated anonymous protein (TRAP), a candidate malaria vaccine antigen, is required for Plasmodium spor

73 Finally, a malaria vaccine antigen, merzoite surface protein 1(42)

74 A recombinant malaria vaccine antigen, the merozoite surface protein 1

75 a emerging from the first phase 3 trial of a malaria vaccine are raising hopes that a licensed vaccin

76 A-175, as one component of a ligand-blocking malaria vaccine, are largely unaffected by polymorphism

77 We have designed and produced a prototypic malaria vaccine based on a highly versatile self-assembl

78 inical testing of a multistage, multiantigen malaria vaccine based on DNA plasmid immunization techno

79 n as TRAP, is included in experimental human malaria vaccines because Plasmodium yoelii SSP2 is the t

80 ion is used to measure efficacy of candidate malaria vaccines before field studies are undertaken.

81 orrelate of protective immunity to the RTS,S malaria vaccine, but few descriptions of the natural var

82 R2CSA is a leading candidate for a pregnancy malaria vaccine, but its large size ( approximately 350

83 as another leading candidate for an asexual malaria vaccine, but without any direct in vivo evidence

84 velopers now moves to the next generation of malaria vaccines, but it is not yet clear what character

85 these obstacles, we constructed an Ad-based malaria vaccine by inserting a B cell epitope derived fr

86 Optimism that a highly effective malaria vaccine can be developed stems in part from the

87 emonstrate that a multicomponent, multistage malaria vaccine can induce immune responses that inhibit

88 ur data suggest that recombinant blood stage malaria vaccines can drive the evolution of more virulen

89 tein-1 (MSP-1) of Plasmodium falciparum is a malaria vaccine candidate Ag.

90 ing the model Ag OVA and leading blood-stage malaria vaccine candidate Ags.

91 RTS,S is an advanced malaria vaccine candidate and confers significant protec

92 Merozoite surface protein-1 (MSP1), a prime malaria vaccine candidate and one of the most abundant c

93 inhibitory activity, bound to the important malaria vaccine candidate antigen, Plasmodium falciparum

94 induced by immunization with two blood-stage malaria vaccine candidate antigens, apical membrane anti

95 izing potential of humoral responses against malaria vaccine candidate antigens.

96 ing is feasible and can rapidly identify new malaria vaccine candidate antigens.

97 cell epitopes identified from asexual-stage malaria vaccine candidate antigens.

98 Antibodies against the malaria vaccine candidate apical membrane antigen-1 (AMA

99 P. vivax DBP is an asexual blood-stage malaria vaccine candidate because adhesion of P. vivax D

100 I trial, an alum formulation of ICC-1132, a malaria vaccine candidate comprising hepatitis B core (H

101 hese studies support ICC-1132 as a promising malaria vaccine candidate for further clinical testing u

102 Following over two decades of research, the malaria vaccine candidate RTS,S has reached the final st

103 Recent phase 3 trials with malaria vaccine candidate RTS,S/AS01 (RTS,S) in children

104 The phase 3 trial of the RTS,S/AS01 malaria vaccine candidate showed modest efficacy of the

105 pical membrane antigen 1 (AMA1) is a leading malaria vaccine candidate that possesses polymorphisms t

106 that encoding the well-established pregnancy malaria vaccine candidate var2csa.

107 ace protein1 (MSP1) is a leading blood-stage malaria vaccine candidate, and anti-MSP1 antibodies from

108 riant surface antigen VAR2CSA is a pregnancy malaria vaccine candidate, but its size and polymorphism

109 to assess the safety and immunogenicity of a malaria vaccine candidate, ICC-1132 (Malarivax), compose

110 though CSP has been extensively studied as a malaria vaccine candidate, little is known about its str

111 The leading malaria vaccine candidate, RTS,S, based on the Plasmodiu

112 een generated that secrete into their milk a malaria vaccine candidate, the 42-kDa C-terminal portion

113 te surface protein, is a leading blood-stage malaria vaccine candidate.

114 courage further clinical development of this malaria vaccine candidate.

115 tect in an animal model, making it a leading malaria vaccine candidate.

116 al toxin 1, currently under development as a malaria vaccine candidate.

117 efore considered a high priority blood-stage malaria vaccine candidate.

118 Current malaria vaccine candidates are directed against human an

119 production and suboptimal immunogenicity of malaria vaccine candidates have slowed the development o

120 The number of malaria vaccine candidates in preclinical and clinical d

121 Evidence from clinical trials of malaria vaccine candidates suggests that both cell-media

122 urface protein 1 (MSP1) is among the leading malaria vaccine candidates that target infection by asex

123 e to express three different AMA1-DiCo-based malaria vaccine candidates to develop a vaccine cocktail

124 tage antigens, to support the development of malaria vaccine candidates, and to search for immunologi

125 To identify novel blood-stage malaria vaccine candidates, we constructed a library of

126 used generally to improve efficacy of other malaria vaccine candidates.

127 xan parasites and are of intense interest as malaria vaccine candidates.

128 denovirus (Ad) serotype 5 has been tested in malaria vaccine clinical trials with excellent safety pr

129 that the further development of PfMSP8 as a malaria vaccine component should focus on the use of PfM

130 A multiple antigen peptide (MAP) malaria vaccine containing minimal Plasmodium falciparum

131 Synthetic peptide malaria vaccines containing the aa 326-345 universal T c

132 Malaria vaccines containing the Plasmodium falciparum Ci

133 As our search for an efficacious malaria vaccine continues, the development of a whole-or

134 An effective malaria vaccine could prove to be the most cost-effectiv

135 It is extremely likely that the malaria vaccines currently in development will be used i

136 , AMA-1, is a component of several candidate malaria vaccines currently in various stages of trials i

137 Important to malaria vaccine design is the phenomenon of "strain-spec

138 Malaria vaccine developers are concerned that antigenic

139 A nonhuman primate model for malaria vaccine development allowing reliable, stringent

140 This knowledge will help to advance malaria vaccine development and suggests that multiple i

141 r malaria vaccines and the recent history of malaria vaccine development and then put forward a manif

142 Malaria vaccine development continues to be hindered by

143 Malaria vaccine development has been dominated by the su

144 A prime target for malaria vaccine development is the circumsporozoite (CS)

145 plexity of the malaria parasite has made the malaria vaccine development process tenuous, advances in

146 A major challenge facing malaria vaccine development programs is identifying effi

147 persistent lack of an effective vaccine, new malaria vaccine development strategies are needed.

148 Successful malaria vaccine development will emphasize definitive fi

149 The next steps for malaria vaccine development will focus on the design of

150 on for an approach to pre-erythrocytic-stage malaria vaccine development, based on the induction of p

151 rasite Plasmodium yoelii (Py) as a model for malaria vaccine development, we have previously shown th

152 ite surface protein 1 (MSP1) is a target for malaria vaccine development.

153 e structure-function information relevant to malaria vaccine development.

154 essing these knowledge gaps could accelerate malaria vaccine development.

155 ation and may have application for pregnancy malaria vaccine development.

156 a parasites and discuss the implications for malaria vaccine development.

157 immunity has long been sought to facilitate malaria vaccine development.

158 rage further exploration of this concept for malaria vaccine development.

159 a parasite P. yoelii, an important model for malaria vaccine development.

160 lciparum is a promising candidate antigen in malaria vaccine development.

161 sults support further studies with Ad5/3 for malaria vaccine development.

162 y, yet it remains neglected as a priority of malaria vaccine development.

163 y understood, which poses a major barrier to malaria vaccine development.

164 arum infections would be highly valuable for malaria vaccine development.

165 y to malaria and have major implications for malaria vaccine development.

166 us ChAd63 are promising delivery systems for malaria vaccines due to their safety profiles and proven

167 oites, we have constructed candidate subunit malaria vaccines expressing six preerythrocytic antigens

168 ortant consideration in the development of a malaria vaccine for individuals living in areas of endem

169 es as economical, safe, and readily produced malaria vaccines for the one-third of the world's popula

170 t skin-based delivery of an adenovirus-based malaria vaccine, HAdV5-PyMSP1(4)(2), to mice using silic

171 The development of an effective malaria vaccine has been hampered by the genetic diversi

172 No injectable malaria vaccine has demonstrated long-term protection ag

173 The RTS,S/AS01E malaria vaccine has moderate efficacy, lower in infants

174 Candidate malaria vaccines have failed to elicit consistently prot

175 sults from recent efficacy trials of HIV and malaria vaccines have instilled hope that another golden

176 for future evaluation and down-selection of malaria vaccine immunogens.

177 fficacy of a single dose adenovirus-vectored malaria vaccine in a mouse model of malaria by co-admini

178 The leading malaria vaccine in development is the circumsporozoite p

179 mains are incorporated in RTS,S, the leading malaria vaccine in phase 3 trials that, to date, protect

180 y of a precisely defined synthetic polyoxime malaria vaccine in volunteers of diverse HLA types.

181 Many malaria vaccines in development rely upon CD8 cells as i

182 mice has not translated readily to effective malaria vaccines in humans.

183 adjuvant effect than alpha-GalCer on HIV and malaria vaccines in mice.

184 GlaxoSmithKline Biologicals SA and PATH Malaria Vaccine Initiative.

185 PATH Malaria Vaccine Initiative; Bill & Melinda Gates Foundat

186 A malaria vaccine is essential if the goal of malaria erad

187 An effective malaria vaccine is needed to address the public health t

188 S,S, have added new vigor to the idea that a malaria vaccine is not only possible but probable.

189 will probably be at least 10 years before a malaria vaccine is ready for widespread use.

190 sporozoite protein (CS), the most successful malaria vaccine is RTS/S, a monovalent CS vaccine.

191 development of a successful ligand-blocking malaria vaccine is the demonstration that antibodies ind

192 nt advances justify optimism that a licensed malaria vaccine is within reach.

193 Novel anti-adherence therapeutics and a malaria vaccine may derived from exploitation of the str

194 The disappointing efficacy of blood-stage malaria vaccines may be explained in part by allele-spec

195 These data suggest that malaria vaccines mimicking naturally acquired immunity s

196 opment effort is named Multi-Stage DNA-based Malaria Vaccine Operation.

197 There are at least 25 projects in the global malaria vaccine pipeline, as well as 47 medicines and 13

198 A live-attenuated malaria vaccine, Plasmodium falciparum sporozoite vaccin

199 ed Ad vastly improves upon Ad as a promising malaria vaccine platform candidate.

200 Development of an effective malaria vaccine poses a major scientific challenge both

201 they may prove to be essential components of malaria vaccine preparations.

202 Three full doses of RTS,S/AS01 malaria vaccine provides partial protection against cont

203 een as a major step forward on the road to a malaria vaccine rather than as arrival at the final dest

204 nical trials of new heterologous prime-boost malaria vaccine regimens using DNA, fowlpox or MVA, have

205 ment of an efficacious Plasmodium falciparum malaria vaccine remains a top priority for global health

206 ies to optimize formulations of multisubunit malaria vaccines require a basic knowledge of underlying

207 Few who were actively engaged in malaria vaccine research 20 years ago (including myself)

208 Vaccination with the pre-erythrocytic malaria vaccine RTS,S induces high levels of antibodies

209 nt that may improve upon the current leading malaria vaccine RTS,S.

210 The candidate malaria vaccine RTS,S/AS01 is being evaluated in order t

211 The candidate malaria vaccine RTS,S/AS01 reduced episodes of both clin

212 The candidate malaria vaccine RTS,S/AS01E has entered phase 3 trials,

213 To further increase the efficacy of malaria vaccine RTS,S/AS02A, we tested the RTS,S antigen

214 One malaria vaccine, RTS,S/AS02, has shown promise in endemi

215 An ideal malaria vaccine should target several stages of the para

216 d immunogenic, the first such virosome-based malaria vaccine showed no protection in a Phase IIa clin

217 ansmissible metabolic mutants as blood-stage malaria vaccine strains.

218 Field-based malaria vaccine studies are in progress to validate the

219 ren aged 6 weeks to 5 years participating in malaria vaccine studies in an area of high malaria and h

220 A multistage malaria vaccine targeting the pre-erythrocytic and sexua

221 iving further impetus for the development of malaria vaccines targeting GLURP.

222 as the development of the new generation of malaria vaccines targeting transmission.

223 The RTS,S/AS01 malaria vaccine targets the circumsporozoite protein, in

224 ome this problem for the leading blood-stage malaria vaccine targets, that is, merozoite surface prot

225 protein to enhance the production of complex malaria vaccine targets.

226 vaccines to maximize the efficacy of a human malaria vaccine that includes immunogenic regions of the

227 infection may be key to the development of a malaria vaccine that induces long-lived protection.

228 latform to develop an efficacious whole-cell malaria vaccine that prevents infection at the preerythr

229 , but the best hope for a highly efficacious malaria vaccine that would improve prospects for malaria

230 nities and challenges inherent in developing malaria vaccines that target the infected hepatocyte.

231 In the field of malaria vaccines, there are many barriers to moving lead

232 under way to improve the efficacy of subunit malaria vaccines through assessments of new adjuvants, v

233 nterventions in teenage girls, such as a new malaria vaccine to be used in pregnancy.

234 ntigenic target for RTS,S, the most advanced malaria vaccine to date.

235 ate antigens and supports the development of malaria vaccines to protect pregnant women.

236 n its critical nature, a phase III human CSP malaria vaccine trial is ongoing.

237 serve as the primary end point in phase III malaria vaccine trials--the first of which will be held

238 The RTS,S/AS01B malaria vaccine warrants comparative field trials with R

239 The triepitope polyoxime malaria vaccine was immunogenic in the absence of any ex

240 To enhance the efficacy of DNA malaria vaccines, we evaluated the effect on protection

241 A recent study of the RTS,S malaria vaccine, which is based on the circumsporozoite

242 Any realistic malaria vaccine will need to optimize proper folding bal

243 argue that rational design of more effective malaria vaccines will be accelerated by a better underst

244 t target populations for asexual blood-stage malaria vaccines will have been exposed to malaria paras

245 An effective malaria vaccine would be a valuable tool to reduce the d

246 A highly protective malaria vaccine would greatly facilitate the prevention